gvtcx

Bleeding Disorders including Haemophilia B

NHS England Published 20 Jul 2022 Contracts Finder

key details

Value£250,000,000
Statuscomplete
Category (CPV) 33141530
RegionScotland, Northern Ireland, Wales
Deadline14 Feb 2022
Contract start1 Jul 2022
Contract end30 Jun 2024
Procedureopen
SME suitableYes
OCIDocds-b5fd17-3223ee06-289a-4576-a570-9458205ac102

Awards (8)

This procurement was awarded to 8 suppliers. Values shown are per-award; the notice total is £250,000,000.

SupplierValueDateStatus
Bio Products Laboratory Ltd shared £250,000,000 14 Jun 2022 active
CSL Behring UK Ltd shared £250,000,000 14 Jun 2022 active
LFB shared £250,000,000 14 Jun 2022 active
Novo Nordisk shared £250,000,000 14 Jun 2022 active
Octapharma Limited shared £250,000,000 14 Jun 2022 active
Pfizer Ltd shared £250,000,000 14 Jun 2022 active
Sobi (Swedish Orphan Biovitrum Ltd) shared £250,000,000 14 Jun 2022 active
Takeda UK Ltd shared £250,000,000 14 Jun 2022 active

description

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B. Period of framework agreement: 1 July 2022 to 30 June 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
7 Jan 2022 Tender (tender) · b9703bc2-cc0f-4908-9288-687a4338bf71-498866
20 Jul 2022 Award (award) · b8e3e14d-0764-46e5-9863-3ae0473aa2e0-556027

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.